SCHEMBL4640486

SCHEMBL4640486

COc1cc(-c2cc(C(=O)NCCNC(=O)c3ccc(C)c(-c4cc(OC)c(OC)c(OC)c4)c3)ccc2C)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 2/20 0.55
RXFP1 Q9HBX9 1/20 0.51
BRD4 O60885 2/20 0.50
FYN P06241 1/20 0.50
NPC1 O15118 1/20 0.49
MAPK14 Q16539 3/20 0.48
POLB P06746 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4640519 0.82 LMNA (0.52) L3MBTL1FYNNPC1POLBMAPK1
SCHEMBL4640436 0.75 NR1H4 (0.54) L3MBTL1MAPK1SMN1; SMN2HPGDTDP1
SCHEMBL5106097 0.74 MAPK14 (0.67) L3MBTL1MAPK14POLB
SCHEMBL6785283 0.73 ALDH1A1 (0.56) L3MBTL1POLBSMN1; SMN2HPGDLMNA
SCHEMBL17689085 0.73 SMPD1 (0.61) L3MBTL1KMT2AMEN1RXFP1BRD4
SCHEMBL4640480 0.73 ABCB1 (0.60) KMT2AMEN1POLBMAPK1SMN1; SMN2
SCHEMBL4640456 0.73 FYN (0.47) KMT2AMEN1BRD4FYNNPC1
SCHEMBL14003414 0.72 MAOB (0.52) RXFP1BRD4FYNPOLBMAPK1
SCHEMBL22580603 0.71 KMT2A (0.69) KMT2AMEN1NPC1POLBSMN1; SMN2
SCHEMBL2926341 0.71 KMT2A (0.77) L3MBTL1KMT2AMEN1RXFP1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934924-B1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2008-08-13 EP disclosed
US-6576642-B2 Inhibitors of the production of Ig E antibodies, antiallergens KOWA CO., LTD. (JP) 2003-06-10 US disclosed
US-20010039279-A1 Diamide compounds and compositions containing the same KOWA CO., LTD. (JP) 2001-11-08 US disclosed
US-6297283-B1 EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS KOWA CO., LTD. (JP) 2001-10-02 US disclosed
EP-0934924-A1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039279-A1 Diamide compounds and compositions containing the same HRH4, HRH2, HRH1 L3MBTL1 1887/4885KMT2A 843/4885MEN1 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.